IntrinsicIntrinsic
← All summaries

Quanome Technologies, Inc.

QNME
Financials & Chart →

Business Summary

Quanome Technologies, Inc. operates in the pharmaceutical distribution industry in China, positioned in the midstream segment between upstream manufacturers and downstream medical end customers. The industry is competitive, with participants across the supply chain, and competition is based on product availability, pricing, supplier and customer relationships, access to hospitals, geographic coverage, procurement capabilities, logistics, regulatory qualifications, financial resources, service quality, and reputation. The company also recently initiated strategic efforts in quantum-related technologies and AI compute capacity and managed inference services, both of which remain in early development stages and have not generated revenue.

The pharmaceutical distribution industry in China is competitive, and the company competes with national and regional distributors, wholesalers, and specialized logistics providers. Certain competitors may have greater financial resources, broader distribution networks, stronger purchasing power, or more established relationships. The company's competitive position relies on maintaining supplier and customer relationships, securing products on acceptable terms, providing reliable services, and responding to market demand and healthcare policies. During fiscal year 2026, the company recognized revenue from more than 60 customers, with approximately four customers accounting for more than 10% of total revenue each.

The company generates revenue primarily through the distribution of pharmaceutical products, including infusion products, foods for special medical purposes, and specialty pharmaceuticals, sold to hospitals, pharmaceutical distributors, and other healthcare providers. Sales are conducted primarily through agents who assist with customer development and order coordination. The company does not manufacture products but sources from multiple manufacturers and suppliers. The business model also includes a newly initiated AI compute capacity and managed inference service, where the subsidiary procures, owns, and operates servers and makes capacity available to customers as a service, with revenue expected from fees for compute capacity and managed infrastructure services.

The pharmaceutical distribution segment, operated through Hupan Pharmaceutical, is the established revenue-generating business. It distributes infusion products, foods for special medical purposes, and specialty pharmaceuticals. The segment's profitability varies by product category, and revenue mix adjustments can offset margin pressure. The company also holds licenses including the Drug Business License, Medical Device Business License, Class II Medical Device Business Filing Certificate, and Food Business License, each with a term of five years.

The AI compute capacity and managed inference services segment, operated through XDT Infrastructure I, LLC, commenced activities in September 2026. The company has entered into an agreement to purchase 32 servers designed for high-performance AI computing workloads. The business model involves procuring, owning, and operating servers and related infrastructure, with capacity logically or physically segregated per customer. Customers may specify AI models to be deployed, and the company does not plan to develop or train proprietary AI models. The segment has not generated revenue or executed customer contracts as of the report date.

During fiscal year 2026, the company completed the disposal of ABL Chicago, its U.S.-based cross-border supply chain solutions business, on February 12, 2026. The company transferred operations to an unrelated third party, which obtained operational control and substantially all economic interests. The company forgave $3,402,808 of amounts due from ABL Chicago and recorded a gain on sale of $2,556,315. The company also changed its corporate name from Lakeside Holding Limited to Quanome Technologies, Inc., effective August 3, 2026, and its common stock began trading under the new ticker symbol 'QNME' on August 4, 2026. Additionally, the company established the Global Quantum Council and Scientific Advisory Network in August 2026.

For the fiscal year ended June 30, 2026, the company's continuing operations focused on pharmaceutical distribution in China. The company recognized revenue from 63 customers, with four customers accounting for over 10% of revenue each. The company wrote off a supplier advance of $2,859,594 (RMB 20,000,000) and recognized a gain on extinguishment of debt of $25,832. The company's financial performance reflects the recast of the disposed ABL Chicago business as discontinued operations.

Business Outlook

A major growth vector is the expansion into AI compute capacity and managed inference services. The company, through XDT Infrastructure I, LLC, commenced activities in September 2026, with an agreement to purchase 32 servers. The business is expected to generate revenue through fees for compute capacity and related managed infrastructure services, including server operation, hosting, model deployment support, API access, monitoring, and related technical services. The company is evaluating customer opportunities and negotiating capacity arrangements, but has no executed customer contracts as of the report date.

Another growth vector is the strategic focus on quantum-related technologies and applications. Through Quantum Nexus, the company is evaluating opportunities in quantum computing, artificial intelligence, advanced simulation, and intelligent systems, with potential applications in therapeutic discovery, healthcare, advanced materials, energy, and cybersecurity. The company announced the establishment of the Global Quantum Council and Scientific Advisory Network in August 2026 to expand access to scientific expertise. These activities remain in the development and evaluation stage, with no revenue generated.

The company's margin and cost outlook is influenced by pricing pressure and competition in the pharmaceutical distribution industry. Government procurement programs and market price competition may compress profit margins. The company expects to manage margins by adjusting the revenue mix of product offerings, as profitability varies among product categories. The company also faces potential increases in operating expenses from new business initiatives, which may require substantial expenditures before generating revenue.

Operationally, the company's pharmaceutical distribution business depends on maintaining relationships with manufacturers, suppliers, and customers. The company leases two premises in Wuhan, China, with a gross floor area of approximately 599 square meters, with lease terms from January 1, 2025 to December 31, 2029, and from March 22, 2026 to March 21, 2027. The executive office in New York has a lease term from September 1, 2026 to August 31, 2027. The company has a workforce of 27 full-time employees as of June 30, 2026.

Capital allocation includes the company's IPO proceeds usage. The company completed its IPO on July 1, 2024, of 1,500,000 shares at $4.50 per share. As of the report date, the company used approximately $3.3 million for marketing activities and business expansion and approximately $2.4 million for working capital needs. The company has never declared or paid cash dividends and does not anticipate doing so. The 2025 Equity Incentive Plan authorizes 5,000,000 shares, with no securities issued as of the report date.

The company faces headwinds from the evolving regulatory environment for AI and quantum technologies, including U.S. export controls on advanced computing equipment. The company may be required to obtain licenses or authorizations for certain transactions, which could restrict customers or jurisdictions served. Additionally, the company's operations in China are subject to PRC government oversight, including cybersecurity reviews and CSRC filing requirements, which could limit capital raising or operations.

The company faces constraints from the early-stage nature of its new business initiatives. The AI compute and managed inference business has limited operating history and may require significant expenditures before generating revenue. The quantum-related activities are in development and evaluation, with no assurance of commercial viability. The company also faces risks from rapid technological change, which could impair the value of its infrastructure and require additional investment.

Risk Factors

The company's pharmaceutical distribution business depends on relationships with manufacturers and suppliers, and any interruption in supply could adversely affect revenue. The industry is competitive, and the company may lose customers to competitors with greater resources. The company's new AI compute and managed inference business is at an early stage and may not develop as expected, requiring significant expenditures before generating revenue. The company faces risks from U.S. export controls on advanced computing equipment, which could restrict customers or jurisdictions served. The company's operations in China are subject to PRC government oversight, including cybersecurity reviews and CSRC filing requirements, which could limit capital raising or operations. The company has material weaknesses in internal control over financial reporting, which could affect accurate reporting. The company's common stock is at risk of delisting from Nasdaq due to non-compliance with the minimum bid price requirement, with a compliance period until January 4, 2027.

Management Priorities

Management's message emphasizes a strategic repositioning from traditional pharmaceutical distribution toward quantum-related technologies and AI compute services. The company changed its name to Quanome Technologies, Inc. to align with this direction. Management highlights the disposal of ABL Chicago as a strategic shift to streamline resources and focus on pharmaceutical distribution while exploring new growth areas. Key priorities include developing AI compute capacity through XDT, evaluating quantum opportunities through Quantum Nexus, and maintaining the pharmaceutical distribution business. Management acknowledges the early stage of new initiatives and the uncertainties involved, but expresses commitment to evaluating opportunities and expanding capabilities.

View Source Annual Report on SEC.gov ↗

References

  1. [1] Item 1, Business — Overview
  2. [2] Item 1, Business — Competition
  3. [3] Item 1, Business — Pharmaceutical Distribution
  4. [4] Item 1, Business — AI Compute Capacity and Managed Inference Services
  5. [5] Item 1, Business — AI Compute Capacity and Managed Inference Services
  6. [6] Item 1, Business — AI Compute Capacity and Managed Inference Services
  7. [7] Item 1, Business — AI Compute Capacity and Managed Inference Services
  8. [8] Item 1, Business — AI Compute Capacity and Managed Inference Services
  9. [9] Item 1, Business — AI Compute Capacity and Managed Inference Services
  10. [10] Item 1, Business — AI Compute Capacity and Managed Inference Services
  11. [11] Item 1, Business — AI Compute Capacity and Managed Inference Services
  12. [12] Item 1, Business — AI Compute Capacity and Managed Inference Services
  13. [13] Item 1, Business — AI Compute Capacity and Managed Inference Services
  14. [14] Item 1, Business — AI Compute Capacity and Managed Inference Services
  15. [15] Item 1, Business — AI Compute Capacity and Managed Inference Services
  16. [16] Item 1, Business — AI Compute Capacity and Managed Inference Services
  17. [17] Item 1, Business — AI Compute Capacity and Managed Inference Services
  18. [18] Item 1, Business — AI Compute Capacity and Managed Inference Services
  19. [19] Item 1, Business — AI Compute Capacity and Managed Inference Services
  20. [20] Item 1, Business — AI Compute Capacity and Managed Inference Services
  21. [21] Item 1, Business — AI Compute Capacity and Managed Inference Services
  22. [22] Item 1, Business — AI Compute Capacity and Managed Inference Services
  23. [23] Item 1, Business — AI Compute Capacity and Managed Inference Services
  24. [24] Item 1, Business — AI Compute Capacity and Managed Inference Services
  25. [25] Item 1, Business — AI Compute Capacity and Managed Inference Services
  26. [26] Item 1, Business — AI Compute Capacity and Managed Inference Services
  27. [27] Item 1, Business — AI Compute Capacity and Managed Inference Services
  28. [28] Item 1, Business — AI Compute Capacity and Managed Inference Services
  29. [29] Item 1, Business — AI Compute Capacity and Managed Inference Services
  30. [30] Item 1, Business — AI Compute Capacity and Managed Inference Services
  31. [31] Item 1, Business — AI Compute Capacity and Managed Inference Services
  32. [32] Item 1, Business — AI Compute Capacity and Managed Inference Services
  33. [33] Item 1, Business — AI Compute Capacity and Managed Inference Services
  34. [34] Item 1, Business — AI Compute Capacity and Managed Inference Services
  35. [35] Item 1, Business — AI Compute Capacity and Managed Inference Services
  36. [36] Item 1, Business — AI Compute Capacity and Managed Inference Services
  37. [37] Item 1, Business — AI Compute Capacity and Managed Inference Services
  38. [38] Item 1, Business — AI Compute Capacity and Managed Inference Services
  39. [39] Item 1, Business — AI Compute Capacity and Managed Inference Services
  40. [40] Item 1, Business — AI Compute Capacity and Managed Inference Services
  41. [41] Item 1, Business — AI Compute Capacity and Managed Inference Services
  42. [42] Item 1, Business — AI Compute Capacity and Managed Inference Services
  43. [43] Item 1, Business — AI Compute Capacity and Managed Inference Services
  44. [44] Item 1, Business — AI Compute Capacity and Managed Inference Services
  45. [45] Item 1, Business — AI Compute Capacity and Managed Inference Services
  46. [46] Item 1, Business — AI Compute Capacity and Managed Inference Services
  47. [47] Item 1, Business — AI Compute Capacity and Managed Inference Services
  48. [48] Item 1, Business — AI Compute Capacity and Managed Inference Services
  49. [49] Item 1, Business — AI Compute Capacity and Managed Inference Services
  50. [50] Item 1, Business — AI Compute Capacity and Managed Inference Services
  51. [51] Item 1, Business — AI Compute Capacity and Managed Inference Services
  52. [52] Item 1, Business — AI Compute Capacity and Managed Inference Services
  53. [53] Item 1, Business — AI Compute Capacity and Managed Inference Services
  54. [54] Item 1, Business — AI Compute Capacity and Managed Inference Services
  55. [55] Item 1, Business — AI Compute Capacity and Managed Inference Services
  56. [56] Item 1, Business — AI Compute Capacity and Managed Inference Services
  57. [57] Item 1, Business — AI Compute Capacity and Managed Inference Services
  58. [58] Item 1, Business — AI Compute Capacity and Managed Inference Services
  59. [59] Item 1, Business — AI Compute Capacity and Managed Inference Services
  60. [60] Item 1, Business — AI Compute Capacity and Managed Inference Services
  61. [61] Item 1, Business — AI Compute Capacity and Managed Inference Services
  62. [62] Item 1, Business — AI Compute Capacity and Managed Inference Services
  63. [63] Item 1, Business — AI Compute Capacity and Managed Inference Services
  64. [64] Item 1, Business — AI Compute Capacity and Managed Inference Services
  65. [65] Item 1, Business — AI Compute Capacity and Managed Inference Services
  66. [66] Item 1, Business — AI Compute Capacity and Managed Inference Services
  67. [67] Item 1, Business — AI Compute Capacity and Managed Inference Services
  68. [68] Item 1, Business — AI Compute Capacity and Managed Inference Services
  69. [69] Item 1, Business — AI Compute Capacity and Managed Inference Services
  70. [70] Item 1, Business — AI Compute Capacity and Managed Inference Services
  71. [71] Item 1, Business — AI Compute Capacity and Managed Inference Services
  72. [72] Item 1, Business — AI Compute Capacity and Managed Inference Services
  73. [73] Item 1, Business — AI Compute Capacity and Managed Inference Services
  74. [74] Item 1, Business — AI Compute Capacity and Managed Inference Services
  75. [75] Item 1, Business — AI Compute Capacity and Managed Inference Services
  76. [76] Item 1, Business — AI Compute Capacity and Managed Inference Services
  77. [77] Item 1, Business — AI Compute Capacity and Managed Inference Services
  78. [78] Item 1, Business — AI Compute Capacity and Managed Inference Services
  79. [79] Item 1, Business — AI Compute Capacity and Managed Inference Services
  80. [80] Item 1, Business — AI Compute Capacity and Managed Inference Services
  81. [81] Item 1, Business — AI Compute Capacity and Managed Inference Services
  82. [82] Item 1, Business — AI Compute Capacity and Managed Inference Services
  83. [83] Item 1, Business — AI Compute Capacity and Managed Inference Services
  84. [84] Item 1, Business — AI Compute Capacity and Managed Inference Services
  85. [85] Item 1, Business — AI Compute Capacity and Managed Inference Services
  86. [86] Item 1, Business — AI Compute Capacity and Managed Inference Services
  87. [87] Item 1, Business — AI Compute Capacity and Managed Inference Services
  88. [88] Item 1, Business — AI Compute Capacity and Managed Inference Services
  89. [89] Item 1, Business — AI Compute Capacity and Managed Inference Services
  90. [90] Item 1, Business — AI Compute Capacity and Managed Inference Services
  91. [91] Item 1, Business — AI Compute Capacity and Managed Inference Services
  92. [92] Item 1, Business — AI Compute Capacity and Managed Inference Services
  93. [93] Item 1, Business — AI Compute Capacity and Managed Inference Services
  94. [94] Item 1, Business — AI Compute Capacity and Managed Inference Services
  95. [95] Item 1, Business — AI Compute Capacity and Managed Inference Services
  96. [96] Item 1, Business — AI Compute Capacity and Managed Inference Services
  97. [97] Item 1, Business — AI Compute Capacity and Managed Inference Services
  98. [98] Item 1, Business — AI Compute Capacity and Managed Inference Services
  99. [99] Item 1, Business — AI Compute Capacity and Managed Inference Services
  100. [100] Item 1, Business — AI Compute Capacity and Managed Inference Services

Analysis on 9/25/2026